Erythrocyte Metabolic Reprogramming by Sphingosine 1-Phosphate in Chronic Kidney Disease and Therapies.

Conclusions: Our study elucidates the beneficial role of erythrocyte Sphk1-S1P in hypertensive CKD by channeling glucose metabolism towards Rapoport-Luebering Shunt and inducing 2,3-BPG production and O2 delivery via a PP2A-AMPK1α signaling pathway. These findings reveal the metabolic and molecular basis of erythrocyte S1P in CKD and new therapeutic avenues.
PMID: 32284030 [PubMed - as supplied by publisher]

Source: Circulation Research - April 13, 2020 Category: Cardiology Authors: Xie T, Chen C, Peng Z, Brown BC, Reisz JA, Xu P, Zhou Z, Song A, Zhang Y, Bogdanov MV, Kellems RE, D'Alessandro A, Zhang W, Xia Y Tags: Circ Res Source Type: research